- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03445468
Immunogenicity and Safety for 'IL-YANG Quadrivalent Influenza Vaccine' in Healthy Korean Children and Adolescents
Phase III Study to Evaluate Immunogenicity and Safety of 'Il-Yang Quadrivalent Seasonal Influenza Vaccine' in Healthy Korean Children and Adolescents
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is an open-label(Part 1), Single-arm(Part 1), Randomized(Part 2), Double-blind(Part 2), Active comparator(Part 2) Phase III study.
Before initiation of any protocol-specific activities, written informed consent is obtained from each patient and their legally acceptable representatives. Subjects who meet all of the eligibility criteria after screening assessments as specified in the protocol, are randomized into the test group or the comparator group in a ratio of 4 :1 and receive a single dose or two doses of the study vaccine. The investigator perform the efficacy (immunogenicity) and safety assessments throughout the study. Efficacy data are collected at Visit 1 (prior to vaccination) and at the end-of-study visit for efficacy (immunogenicity) assessments, and for safety assessment, subjects and their legally acceptable representatives are instructed to record any treatment-emergent adverse event in Patient Diary cards.
For all randomized subjects, blood sample is obtained prior to vaccination, and the study vaccine 0.5mL is administered. For children aged from 3 years to <9 years of age who have not previously received influenza vaccine, another dose of the study vaccine is administered 4 to 5 weeks after the first dose. Blood samples are collected 4 to 5 weeks after the last dose of the study drug for the assessment of antibody titer. All subjects are followed for 6 months after the last dose of the study drug for the safety assessments, and Month 6 follow-up visit is the end-of-study visit.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 06591
- The catholic university of Korea, Seoul ST. Marry's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy men or women aged from 3 years to < 19 years
- Subjects were born after full term pregnancy (37 weeks)
- Woman of childbearing potential must have a negative result from Urine Human Chorionic Gonadotropin(HCG) test at the screening visit.
- Voluntary written informed consent was obtained from the subject and the subject's legally acceptable representative (consent of legally acceptable representative was required for subjects younger than 7 years of age)
Exclusion Criteria:
- Subject with a known serious allergy reaction after influenza vaccination or to any component vaccine including eggs
- Subject who had received an influenza vaccine within the last 6 months
- Subject who has, or has a family history of, an immune system disorder including immune deficiency disease
- Subject with a history of Guillain-Barre syndrome
- Subject with Down's syndrome or cytogenetic disorders.
- Subject with severe chronic disease which in the investigator's opinion would not make the subject a good candidate for the clinical trial
- Subject with hemophilia or being treated with an anticoagulant, who are at increased risk of serious bleeding during intramuscular injection
- Subject who had an acute fever with body temperature > 38.0 Cº within 72 hours prior to administration of the study vaccine
- Subject who had previously received another vaccine within 28 days before administration of the study drug, or is scheduled to receive another vaccine during the study period.
- Subject who had received immunosuppressant or immune modifying drug within the last 3 months prior to administration of the study vaccine
- Subject who had previously received immunoglobulin or blood-derived products within the last 3 months prior to administration of the study vaccine, or is expecting to be treated with immunoglobulin or blood-derived products during the study.
- Subject who had participated in another experimental study within 28 days prior to administration of the study vaccine
- Subject with other clinically significant medical or psychological condition who in the investigator's opinion would not be suitable for the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IL-YANG Quadrivalent Influenza Vaccine
The vaccine contains both B strain (Yamagata, Victoria)
|
A single 0.5mL dose administrated as an intramuscular injection.
|
Active Comparator: IL-YANG Flu Vaccine Pre-filled Syringe
The vaccine contains the B/Yamagata strain and it was approved for commercial sale by Ministry of Food and Drug Safety.
|
A single 0.5mL dose administrated as an intramuscular injection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Seroconversion rate against Hemagglutination Inhibition(HI) antibody
Time Frame: Up to Day28(+7) after the last vaccination
|
Seroconversion rate(a lower bound of 95 CI) ≥ 40%
|
Up to Day28(+7) after the last vaccination
|
Seroprotection rate against Hemagglutination
Time Frame: Up to Day28(+7) after the last vaccination
|
Seroprotection rate(a lower bound of 95 CI) ≥ 70%
|
Up to Day28(+7) after the last vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Geometric Mean Titer(GMT) and Geometric Mean Ratio(GMR)
Time Frame: Up to Day28(+7) after the last vaccination
|
GMT and GMR of HI Antibody Titer Before Vaccination and After Vaccination
|
Up to Day28(+7) after the last vaccination
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jin-Han Kang, MD.PhD, The catholic university of Korea, Seoul ST. Marry's Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IF4CH03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza, Human
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
AVIR Green Hills Biotechnology AGCompletedSeasonal Human InfluenzaAustria
-
Fluart Innovative Vaccine Ltd, HungaryCompleted
-
Research Institute for Biological Safety ProblemsResearch Institute of Influenza, Russia; Asfendiyarov Kazakh National Medical...Completed
-
Novartis VaccinesCompleted
-
Novartis VaccinesCompleted
-
Emergent BioSolutionsCompleted
-
Novartis VaccinesCompleted
-
Novartis VaccinesCompleted
-
Novartis VaccinesCompleted
Clinical Trials on IL-YANG Quadrivalent Influenza Vaccine
-
Il-Yang Pharm. Co., Ltd.Completed
-
Emory UniversityRecruitingFollicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Mature T-Cell and NK-Cell Non-Hodgkin LymphomaUnited States
-
Sanofi Pasteur, a Sanofi CompanyRecruitingInfluenza ImmunizationUnited States, Puerto Rico
-
Il-Yang Pharm. Co., Ltd.CompletedHealthyKorea, Republic of
-
Il-Yang Pharm. Co., Ltd.Completed
-
Sanofi Pasteur, a Sanofi CompanyActive, not recruitingInfluenza ImmunizationAustralia, United States, Puerto Rico
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza ImmunizationPuerto Rico, United States
-
Sinovac Biotech Co., LtdRecruitingA Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 MonthsSeasonal InfluenzaChina
-
Sinovac Biotech Co., LtdRecruitingSeasonal InfluenzaChina
-
PfizerCompletedInfluenza, HumanUnited States, Brazil, South Africa, Philippines, New Zealand, Chile, Argentina